AEZS-130 (formerly ARD-07) — Competitive Intelligence Brief

AEZS-130 (formerly ARD-07) (AEZS-130 (formerly ARD-07)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen receptor antagonist. Area: Oncology.

phase 3 Androgen receptor antagonist Androgen receptor (AR) Oncology Small molecule

Target snapshot

AEZS-130 (formerly ARD-07) (AEZS-130 (formerly ARD-07)) — AEterna Zentaris. AEZS-130 is a selective androgen receptor (AR) antagonist that blocks androgen signaling in hormone-sensitive cancers.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AEZS-130 (formerly ARD-07) TARGET	AEZS-130 (formerly ARD-07)	AEterna Zentaris	phase 3	Androgen receptor antagonist	Androgen receptor (AR)
Maximum androgen blockade	Maximum androgen blockade	Wonju Severance Christian Hospital	marketed	Androgen receptor antagonist combination therapy	Androgen receptor; testosterone synthesis pathway
ODM-201 Tablet A	ODM-201 Tablet A	Orion Corporation, Orion Pharma	marketed	Androgen receptor antagonist	Androgen receptor (AR)
Darolutamide Oral Tablet	Darolutamide Oral Tablet	Santa Chiara Hospital	marketed	Androgen receptor antagonist	Androgen receptor (AR)
Zoladex and Casodex	Zoladex and Casodex	AstraZeneca	marketed	GnRH agonist (Zoladex) and androgen receptor antagonist (Casodex)	GnRH receptor (Zoladex); androgen receptor (Casodex)
Antiandrogen+docetaxel	Antiandrogen+docetaxel	Göteborg University	phase 3	Combination therapy: androgen receptor antagonist + taxane chemotherapy	Androgen receptor (AR) and microtubule-associated proteins
Darolutamide continuous	Darolutamide continuous	The First Affiliated Hospital with Nanjing Medical University	phase 3	Androgen receptor antagonist	Androgen receptor (AR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen receptor antagonist class)

1. Santa Chiara Hospital · 2 drugs in this class
2. Cassiopea SpA · 2 drugs in this class
3. The First Affiliated Hospital with Nanjing Medical University · 2 drugs in this class
4. Pfizer · 2 drugs in this class
5. Suzhou Kintor Pharmaceutical Inc, · 1 drug in this class
6. AEterna Zentaris · 1 drug in this class
7. University of Sydney · 1 drug in this class
8. CHU de Quebec-Universite Laval · 1 drug in this class
9. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
10. Orion Corporation, Orion Pharma · 1 drug in this class